Can we unlock the body’s ability to heal itself after spinal cord injury, stroke, or ALS? According to Mike Kelly, President and CEO of NervGen, the answer lies in innovative biotech that targets the nervous system at the molecular level — not just to slow decline, but to promote real regeneration.

With over 30 years in the pharmaceutical space, Mike is now leading NervGen through some of its most exciting breakthroughs yet. Their lead drug candidate, NVG-291, is currently being tested in a Phase 1b/2a clinical trial for spinal cord injury. They’ve also launched preclinical evaluation for NVG-300 — a new compound with the potential to transform treatment for ischemic stroke, ALS, and other neurodegenerative conditions.

Join us as we explore:

• How NervGen’s technology helps “unlock” the nervous system’s healing potential
• What clinical trials reveal about the body’s ability to rewire itself
• Why biomarkers are essential for tracking progress and breakthroughs

Stay updated on NervGen’s work by visiting their official website — and discover where neuroscience meets possibility.

Episode also available on Apple Podcasts: https://apple.co/38oMlMr